Uringebundene Diagnostik
Autor: | Stefan H. Hautmann, Klaus P. Juenemann, Vinata B. Lokeshwar |
---|---|
Rok vydání: | 2009 |
Předmět: |
Gynecology
medicine.medical_specialty Bladder cancer medicine.diagnostic_test business.industry Urology Tumor specific Cystoscopy urologic and male genital diseases medicine.disease female genital diseases and pregnancy complications medicine Current mode Radiology Stage (cooking) business Urine cytology |
Zdroj: | Der Urologe. 48:619-624 |
ISSN: | 1433-0563 0340-2592 |
Popis: | The heterogeneity of bladder tumors in their ability to invade and metastasize and their frequent recurrence pose a challenge for physicians who treat bladder cancer patients and for the researchers who work on bladder cancer diagnosis, recurrence, and treatment-related areas. For most new bladder cancer cases, investigation begins when patients are symptomatic (i.e., hematuria or irritative voiding). This mode of detection is often inadequate for nearly 15-30% of these new cases with high-grade bladder cancer, since the tumor is already in the invasive stage at the time of diagnosis. Bladder cancer patients are on a mandatory 3-month to 6-month surveillance schedule because bladder tumors frequently recur. The current mode of detecting bladder cancer involves cystoscopy, which is an invasive and relatively expensive procedure. Voided urine cytology, the standard noninvasive marker, is highly tumor specific and has good sensitivity for detecting high-grade tumors. However, its sensitivity for detecting low-grade tumors is low; its accuracy depends on the examiner’s expertise; and it is not available everywhere. Marker systems are readily available for use in practice. Their utility remains under discussion. |
Databáze: | OpenAIRE |
Externí odkaz: |